NR 546 Advanced Psychopharmacology — Midterm Examination (2026/2027) Chamberlain University
NR 546 Advanced Psychopharmacology
Midterm Examination — Newest 2026/2027 Edition
Includes Accurate and Verified Questions Covering Advanced Psychopharmacology, Including
Medication Management for Psychiatric-Mental Health Nurse Practitioner Practice
Chamberlain University • College of Nursing • Graduate Program
Examination Instructions: This midterm examination contains 150 multiple-choice questions distributed across nine (9)
content domains. Each question has one best answer. Questions are 75% scenario-based and 25% direct recall, calibrated to
cognitive levels of 25% recall, 55% application, and 20% analysis. Rationales following each question incorporate
neurobiological mechanisms, receptor pharmacology, CYP450 metabolism, evidence-based guidelines, and prescriptive
safety considerations. Black-box warnings, therapeutic drug monitoring parameters, and FDA-approved indications are
emphasized throughout. Allow approximately 180 minutes for completion.
Section 1: Foundations of Psychopharmacology (Q1–Q18)
Neurotransmitters, Receptors, Pharmacokinetics, & Pharmacodynamics in CNS
Q1. A 34-year-old graduate student is prescribed an SSRI for major depressive disorder. The PMHNP explains
that the therapeutic benefit of SSRIs is achieved not by the immediate blockade of the serotonin transporter
(SERT) but by downstream neuroadaptive changes. Which of the following best describes the receptor-level
mechanism that ultimately produces the antidepressant effect of SSRIs?
A. Immediate and sustained blockade of 5-HT1A autoreceptors on raphe nuclei neurons
B. Progressive downregulation and desensitization of somatodendritic 5-HT1A autoreceptors, allowing enhanced
serotonergic neurotransmission at synaptic terminals [CORRECT]
C. Direct agonism at postsynaptic 5-HT2A receptors in the prefrontal cortex
D. Inhibition of presynaptic vesicular monoamine transporter 2 (VMAT2) activity, increasing cytoplasmic
serotonin stores
Correct Answer: B
Rationale: SSRIs produce an acute increase in synaptic serotonin within hours by blocking SERT, but clinical
antidepressant effects require 2–6 weeks. This delay reflects the progressive downregulation and desensitization of
somatodendritic 5-HT1A autoreceptors in the dorsal raphe nucleus; once these autoreceptors desensitize, serotonergic
neuron firing normalizes and terminal serotonin release increases postsynaptically. Option A is incorrect because
acute 5-HT1A autoreceptor blockade alone (e.g., by pindolol augmentation) may hasten response but is not the
primary SSRI mechanism. Option C incorrectly attributes the effect to 5-HT2A agonism, which would more closely
resemble psychedelic pharmacology. Option D describes VMAT2 inhibition (e.g., tetrabenazine), which is not the SSRI
mechanism.
Verified • Accurate • Aligned with 2026/2027 PMHNP Standards Page 1
,NR 546 Advanced Psychopharmacology — Midterm Examination (2026/2027) Chamberlain University
Q2. A patient with schizophrenia on a high-potency first-generation antipsychotic (FGA) develops acute muscle
spasms of the neck and jaw two days after initiation. The PMHNP recognizes this as acute dystonia. Which
dopaminergic pathway is most directly implicated in both the antipsychotic efficacy of FGAs and the emergence
of this adverse effect?
A. Mesolimbic pathway (ventral tegmental area to nucleus accumbens)
B. Mesocortical pathway (ventral tegmental area to prefrontal cortex)
C. Nigrostriatal pathway (substantia nigra pars compacta to dorsal striatum) [CORRECT]
D. Tuberoinfundibular pathway (arcuate nucleus of hypothalamus to pituitary)
Correct Answer: C
Rationale: First-generation antipsychotics produce therapeutic effects by D2 receptor antagonism in the mesolimbic
pathway (positive symptom control), but their motor adverse effects arise from off-target D2 blockade in the
nigrostriatal pathway, which is part of the extrapyramidal motor system. Acute dystonia results from acute D2
blockade disrupting the balance between direct and indirect basal ganglia pathways. The mesolimbic pathway (A) is
the target for antipsychotic efficacy, not EPS. The mesocortical pathway (B) is implicated in negative and cognitive
symptoms. The tuberoinfundibular pathway (D) D2 blockade causes hyperprolactinemia, not motor adverse effects.
Q3. A PMHNP is teaching a patient about norepinephrine pharmacology. Which enzyme catalyzes the
rate-limiting step in norepinephrine synthesis, converting tyrosine to L-DOPA?
A. Dopamine β-hydroxylase
B. Dopa decarboxylase (aromatic L-amino acid decarboxylase)
C. Tyrosine hydroxylase [CORRECT]
D. Phenylethanolamine N-methyltransferase (PNMT)
Correct Answer: C
Rationale: Tyrosine hydroxylase catalyzes the conversion of tyrosine to L-DOPA and is the rate-limiting enzyme in
catecholamine synthesis, including norepinephrine, dopamine, and epinephrine. Dopamine β-hydroxylase (A) converts
dopamine to norepinephrine inside vesicles. Dopa decarboxylase (B) converts L-DOPA to dopamine. PNMT (D)
converts norepinephrine to epinephrine, primarily in the adrenal medulla. Inhibition of tyrosine hydroxylase (e.g., by
alpha-methyl-para-tyrosine) depletes catecholamines and is used rarely in resistant hypertension or
pheochromocytoma management.
Verified • Accurate • Aligned with 2026/2027 PMHNP Standards Page 2
,NR 546 Advanced Psychopharmacology — Midterm Examination (2026/2027) Chamberlain University
Q4. A 42-year-old patient presents with benzodiazepine overdose. The PMHNP understands that
benzodiazepines allosterically modulate the GABA-A receptor. Which of the following best describes the
receptor-level action of benzodiazepines at GABA-A?
A. They directly open the chloride channel independent of GABA binding
B. They bind at the interface of α and γ subunits and increase the frequency of chloride channel opening in
response to GABA [CORRECT]
C. They antagonize the GABA-B receptor, increasing neuronal firing
D. They bind the GABA recognition site on the β subunit and act as full agonists
Correct Answer: B
Rationale: Benzodiazepines are positive allosteric modulators at GABA-A receptors. They bind at the interface of α
(α1, α2, α3, or α5) and γ2 subunits and increase the frequency (not duration) of chloride channel opening in response
to GABA, producing hyperpolarization and reduced neuronal excitability. They have no intrinsic activity without
GABA present, distinguishing them from direct agonists like barbiturates, which open the channel independently (A).
GABA-B receptors (C) are metabotropic, G-protein coupled, and not benzodiazepine targets. The GABA recognition
site is on the β subunit (D), not the benzodiazepine site.
Q5. A patient is being considered for ketamine augmentation in treatment-resistant depression. The PMHNP
recognizes that ketamine's rapid antidepressant effect is mediated primarily through which glutamatergic
mechanism?
A. Antagonism of the NMDA receptor, leading to a surge in presynaptic glutamate and activation of AMPA
receptors and mTOR signaling [CORRECT]
B. Direct agonism at the AMPA receptor, increasing synaptic plasticity
C. Inhibition of glutamate uptake by astrocytic EAAT2 transporters
D. Blockade of metabotropic glutamate receptor 5 (mGluR5)
Correct Answer: A
Rationale: Ketamine is a non-competitive NMDA receptor antagonist. Its antidepressant effect is thought to result
from preferential blockade of NMDA receptors on GABAergic interneurons, disinhibiting prefrontal glutamatergic
pyramidal neurons. The resulting surge in extracellular glutamate activates AMPA receptors and downstream mTOR
signaling, increasing synaptogenesis and BDNF expression within hours. This contrasts with monoaminergic
antidepressants, which take weeks. Direct AMPA agonism (B), EAAT2 inhibition (C), and mGluR5 blockade (D) are
not the primary ketamine mechanism, though mGluR5 negative allosteric modulators are being investigated as
antidepressant agents.
Verified • Accurate • Aligned with 2026/2027 PMHNP Standards Page 3
, NR 546 Advanced Psychopharmacology — Midterm Examination (2026/2027) Chamberlain University
Q6. An 82-year-old patient on a medication with potent anticholinergic properties develops confusion, dry
mouth, urinary retention, and constipation. Which receptor pharmacology best explains this cluster of adverse
effects?
A. Antagonism of muscarinic M1 receptors in the CNS and peripheral tissues [CORRECT]
B. Antagonism of nicotinic N1 receptors at autonomic ganglia
C. Agonism at α-adrenergic receptors in the genitourinary tract
D. Inhibition of acetylcholinesterase at peripheral synapses
Correct Answer: A
Rationale: The classic anticholinergic toxidrome — dry mouth, blurred vision, urinary retention, constipation,
tachycardia, and confusion — results from antagonism of muscarinic acetylcholine receptors, particularly M1 and M3
subtypes. Many psychotropics (TCAs, low-potency FGAs, diphenhydramine, oxybutynin) carry significant
anticholinergic burden and are particularly hazardous in older adults per the Beers Criteria. Nicotinic receptor
blockade (B) produces ganglionic blockade and neuromuscular effects. α-adrenergic agonism (C) may cause urinary
retention but not the full anticholinergic syndrome. Acetylcholinesterase inhibition (D) produces a cholinergic (excess
acetylcholine) picture opposite to this presentation.
Q7. A PMHNP explains to a student why chronic SSRI therapy requires several weeks before clinical
improvement is appreciated. This delay is most accurately explained by which pharmacodynamic concept?
A. Time to reach steady-state plasma concentration (typically 5 half-lives)
B. Slow accumulation of active metabolites that exert antidepressant effects
C. Receptor downregulation and postsynaptic neuroadaptive changes, including upregulated BDNF expression
and neurogenesis in the hippocampus [CORRECT]
D. Delayed achievement of therapeutic drug levels in cerebrospinal fluid
Correct Answer: C
Rationale: SSRIs reach steady-state plasma levels within about 5 half-lives (days, not weeks), so plasma kinetics alone
cannot explain the therapeutic lag. The delayed onset reflects downstream neuroadaptive changes, including
desensitization of 5-HT1A autoreceptors, increased BDNF expression, enhanced neurogenesis in the hippocampus,
and remodeling of dendritic spine density in the prefrontal cortex. These changes require sustained exposure. While
some SSRIs have active metabolites (e.g., norfluoxetine), metabolite accumulation (B) is not the rate-limiting factor for
efficacy. CSF penetration (D) occurs rapidly. The receptor-level adaptation remains the best-supported explanation.
Verified • Accurate • Aligned with 2026/2027 PMHNP Standards Page 4
NR 546 Advanced Psychopharmacology
Midterm Examination — Newest 2026/2027 Edition
Includes Accurate and Verified Questions Covering Advanced Psychopharmacology, Including
Medication Management for Psychiatric-Mental Health Nurse Practitioner Practice
Chamberlain University • College of Nursing • Graduate Program
Examination Instructions: This midterm examination contains 150 multiple-choice questions distributed across nine (9)
content domains. Each question has one best answer. Questions are 75% scenario-based and 25% direct recall, calibrated to
cognitive levels of 25% recall, 55% application, and 20% analysis. Rationales following each question incorporate
neurobiological mechanisms, receptor pharmacology, CYP450 metabolism, evidence-based guidelines, and prescriptive
safety considerations. Black-box warnings, therapeutic drug monitoring parameters, and FDA-approved indications are
emphasized throughout. Allow approximately 180 minutes for completion.
Section 1: Foundations of Psychopharmacology (Q1–Q18)
Neurotransmitters, Receptors, Pharmacokinetics, & Pharmacodynamics in CNS
Q1. A 34-year-old graduate student is prescribed an SSRI for major depressive disorder. The PMHNP explains
that the therapeutic benefit of SSRIs is achieved not by the immediate blockade of the serotonin transporter
(SERT) but by downstream neuroadaptive changes. Which of the following best describes the receptor-level
mechanism that ultimately produces the antidepressant effect of SSRIs?
A. Immediate and sustained blockade of 5-HT1A autoreceptors on raphe nuclei neurons
B. Progressive downregulation and desensitization of somatodendritic 5-HT1A autoreceptors, allowing enhanced
serotonergic neurotransmission at synaptic terminals [CORRECT]
C. Direct agonism at postsynaptic 5-HT2A receptors in the prefrontal cortex
D. Inhibition of presynaptic vesicular monoamine transporter 2 (VMAT2) activity, increasing cytoplasmic
serotonin stores
Correct Answer: B
Rationale: SSRIs produce an acute increase in synaptic serotonin within hours by blocking SERT, but clinical
antidepressant effects require 2–6 weeks. This delay reflects the progressive downregulation and desensitization of
somatodendritic 5-HT1A autoreceptors in the dorsal raphe nucleus; once these autoreceptors desensitize, serotonergic
neuron firing normalizes and terminal serotonin release increases postsynaptically. Option A is incorrect because
acute 5-HT1A autoreceptor blockade alone (e.g., by pindolol augmentation) may hasten response but is not the
primary SSRI mechanism. Option C incorrectly attributes the effect to 5-HT2A agonism, which would more closely
resemble psychedelic pharmacology. Option D describes VMAT2 inhibition (e.g., tetrabenazine), which is not the SSRI
mechanism.
Verified • Accurate • Aligned with 2026/2027 PMHNP Standards Page 1
,NR 546 Advanced Psychopharmacology — Midterm Examination (2026/2027) Chamberlain University
Q2. A patient with schizophrenia on a high-potency first-generation antipsychotic (FGA) develops acute muscle
spasms of the neck and jaw two days after initiation. The PMHNP recognizes this as acute dystonia. Which
dopaminergic pathway is most directly implicated in both the antipsychotic efficacy of FGAs and the emergence
of this adverse effect?
A. Mesolimbic pathway (ventral tegmental area to nucleus accumbens)
B. Mesocortical pathway (ventral tegmental area to prefrontal cortex)
C. Nigrostriatal pathway (substantia nigra pars compacta to dorsal striatum) [CORRECT]
D. Tuberoinfundibular pathway (arcuate nucleus of hypothalamus to pituitary)
Correct Answer: C
Rationale: First-generation antipsychotics produce therapeutic effects by D2 receptor antagonism in the mesolimbic
pathway (positive symptom control), but their motor adverse effects arise from off-target D2 blockade in the
nigrostriatal pathway, which is part of the extrapyramidal motor system. Acute dystonia results from acute D2
blockade disrupting the balance between direct and indirect basal ganglia pathways. The mesolimbic pathway (A) is
the target for antipsychotic efficacy, not EPS. The mesocortical pathway (B) is implicated in negative and cognitive
symptoms. The tuberoinfundibular pathway (D) D2 blockade causes hyperprolactinemia, not motor adverse effects.
Q3. A PMHNP is teaching a patient about norepinephrine pharmacology. Which enzyme catalyzes the
rate-limiting step in norepinephrine synthesis, converting tyrosine to L-DOPA?
A. Dopamine β-hydroxylase
B. Dopa decarboxylase (aromatic L-amino acid decarboxylase)
C. Tyrosine hydroxylase [CORRECT]
D. Phenylethanolamine N-methyltransferase (PNMT)
Correct Answer: C
Rationale: Tyrosine hydroxylase catalyzes the conversion of tyrosine to L-DOPA and is the rate-limiting enzyme in
catecholamine synthesis, including norepinephrine, dopamine, and epinephrine. Dopamine β-hydroxylase (A) converts
dopamine to norepinephrine inside vesicles. Dopa decarboxylase (B) converts L-DOPA to dopamine. PNMT (D)
converts norepinephrine to epinephrine, primarily in the adrenal medulla. Inhibition of tyrosine hydroxylase (e.g., by
alpha-methyl-para-tyrosine) depletes catecholamines and is used rarely in resistant hypertension or
pheochromocytoma management.
Verified • Accurate • Aligned with 2026/2027 PMHNP Standards Page 2
,NR 546 Advanced Psychopharmacology — Midterm Examination (2026/2027) Chamberlain University
Q4. A 42-year-old patient presents with benzodiazepine overdose. The PMHNP understands that
benzodiazepines allosterically modulate the GABA-A receptor. Which of the following best describes the
receptor-level action of benzodiazepines at GABA-A?
A. They directly open the chloride channel independent of GABA binding
B. They bind at the interface of α and γ subunits and increase the frequency of chloride channel opening in
response to GABA [CORRECT]
C. They antagonize the GABA-B receptor, increasing neuronal firing
D. They bind the GABA recognition site on the β subunit and act as full agonists
Correct Answer: B
Rationale: Benzodiazepines are positive allosteric modulators at GABA-A receptors. They bind at the interface of α
(α1, α2, α3, or α5) and γ2 subunits and increase the frequency (not duration) of chloride channel opening in response
to GABA, producing hyperpolarization and reduced neuronal excitability. They have no intrinsic activity without
GABA present, distinguishing them from direct agonists like barbiturates, which open the channel independently (A).
GABA-B receptors (C) are metabotropic, G-protein coupled, and not benzodiazepine targets. The GABA recognition
site is on the β subunit (D), not the benzodiazepine site.
Q5. A patient is being considered for ketamine augmentation in treatment-resistant depression. The PMHNP
recognizes that ketamine's rapid antidepressant effect is mediated primarily through which glutamatergic
mechanism?
A. Antagonism of the NMDA receptor, leading to a surge in presynaptic glutamate and activation of AMPA
receptors and mTOR signaling [CORRECT]
B. Direct agonism at the AMPA receptor, increasing synaptic plasticity
C. Inhibition of glutamate uptake by astrocytic EAAT2 transporters
D. Blockade of metabotropic glutamate receptor 5 (mGluR5)
Correct Answer: A
Rationale: Ketamine is a non-competitive NMDA receptor antagonist. Its antidepressant effect is thought to result
from preferential blockade of NMDA receptors on GABAergic interneurons, disinhibiting prefrontal glutamatergic
pyramidal neurons. The resulting surge in extracellular glutamate activates AMPA receptors and downstream mTOR
signaling, increasing synaptogenesis and BDNF expression within hours. This contrasts with monoaminergic
antidepressants, which take weeks. Direct AMPA agonism (B), EAAT2 inhibition (C), and mGluR5 blockade (D) are
not the primary ketamine mechanism, though mGluR5 negative allosteric modulators are being investigated as
antidepressant agents.
Verified • Accurate • Aligned with 2026/2027 PMHNP Standards Page 3
, NR 546 Advanced Psychopharmacology — Midterm Examination (2026/2027) Chamberlain University
Q6. An 82-year-old patient on a medication with potent anticholinergic properties develops confusion, dry
mouth, urinary retention, and constipation. Which receptor pharmacology best explains this cluster of adverse
effects?
A. Antagonism of muscarinic M1 receptors in the CNS and peripheral tissues [CORRECT]
B. Antagonism of nicotinic N1 receptors at autonomic ganglia
C. Agonism at α-adrenergic receptors in the genitourinary tract
D. Inhibition of acetylcholinesterase at peripheral synapses
Correct Answer: A
Rationale: The classic anticholinergic toxidrome — dry mouth, blurred vision, urinary retention, constipation,
tachycardia, and confusion — results from antagonism of muscarinic acetylcholine receptors, particularly M1 and M3
subtypes. Many psychotropics (TCAs, low-potency FGAs, diphenhydramine, oxybutynin) carry significant
anticholinergic burden and are particularly hazardous in older adults per the Beers Criteria. Nicotinic receptor
blockade (B) produces ganglionic blockade and neuromuscular effects. α-adrenergic agonism (C) may cause urinary
retention but not the full anticholinergic syndrome. Acetylcholinesterase inhibition (D) produces a cholinergic (excess
acetylcholine) picture opposite to this presentation.
Q7. A PMHNP explains to a student why chronic SSRI therapy requires several weeks before clinical
improvement is appreciated. This delay is most accurately explained by which pharmacodynamic concept?
A. Time to reach steady-state plasma concentration (typically 5 half-lives)
B. Slow accumulation of active metabolites that exert antidepressant effects
C. Receptor downregulation and postsynaptic neuroadaptive changes, including upregulated BDNF expression
and neurogenesis in the hippocampus [CORRECT]
D. Delayed achievement of therapeutic drug levels in cerebrospinal fluid
Correct Answer: C
Rationale: SSRIs reach steady-state plasma levels within about 5 half-lives (days, not weeks), so plasma kinetics alone
cannot explain the therapeutic lag. The delayed onset reflects downstream neuroadaptive changes, including
desensitization of 5-HT1A autoreceptors, increased BDNF expression, enhanced neurogenesis in the hippocampus,
and remodeling of dendritic spine density in the prefrontal cortex. These changes require sustained exposure. While
some SSRIs have active metabolites (e.g., norfluoxetine), metabolite accumulation (B) is not the rate-limiting factor for
efficacy. CSF penetration (D) occurs rapidly. The receptor-level adaptation remains the best-supported explanation.
Verified • Accurate • Aligned with 2026/2027 PMHNP Standards Page 4
